comparemela.com

Latest Breaking News On - Bladder cancer company - Page 7 : comparemela.com

Photocure Partner Asieris announces that the First Non-Vaccine Investigational Product for Cervical HSIL has Achieved It

OSLO, Norway, Sept. 20, 2023 /PRNewswire/ Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces.

Ceophotocure asaemailJinghe langRelationsphotocure asatelLinda wuDan schneiderpresidentPrnewswire photocureDavid moskowitzviceErik dahlcfophotocure asatelAnders neijberCorporate communications norway telAcademy member drChinese national medical products administrationChinese eugenics associationOslo stock exchangeCervical pathology branchChinese academy of medical sciences

Photocure ASA: Results for the second quarter and first half of 2023 - Invesco Water Resources ETF (NASDAQ:PHO)

OSLO, Norway, Aug. 9, 2023 /PRNewswire/ Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 115.9 million in the second quarter of 2023 (Q2 2022: NOK 99.9 million), and an EBITDA of NOK

United statesDan schneiderTolv hillestadPrnewswire photocureHexvix cysviewDavid moskowitzRobert blattKarl storzJanh egbertsErik dahlChairperson of the company board directorsCorporate communications norwayNomination committeeBladder cancer companyPhotocure nomination committeeOslo stock exchange

Photocure ASA: Results for the second quarter and first half of 2023

/PRNewswire/ Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 115.9 million in the second quarter of 2023 (Q2 2022: NOK 99.9.

United statesHexvix cysviewPrnewswire photocureJanh egbertsErik dahlDavid moskowitzRobert blattDan schneiderKarl storzTolv hillestadChairperson of the company board directorsNomination committeePhotocure nomination committeeBladder cancer companyOslo stock exchangeCorporate communications norway

Photocure Partner Asieris announces completion of enrollment for Hexvix Phase III clinical trial in China - Invesco Water Resources ETF (NASDAQ:PHO)

OSLO, Norway, July 6, 2023 /PRNewswire/ Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) has communicated today that it has completed patient

United statesNew zealandLi hanzhongErik dahlDan schneiderHexvix cysviewCysview hexvixDavid moskowitzPrnewswire photocureChinese academy of medical sciencesNational medical products administrationBladder cancer companyAsieris pharmaceuticalsOslo stock exchangeCorporate communications norwayUnion medical college hospital

Photocure Partner Asieris announces completion of enrollment for Hexvix Phase III clinical trial in China

/PRNewswire/ Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) has communicated today.

New zealandUnited statesPrnewswire photocureDavid moskowitzLi hanzhongHexvix cysviewCysview hexvixDan schneiderErik dahlOslo stock exchangeBladder cancer companyAsieris pharmaceuticalsNational medical products administrationChinese academy of medical sciencesCorporate communications norwayAmerican cancer society

vimarsana © 2020. All Rights Reserved.